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Peroxisome proliferator-activated receptor (PPAR) are nuclear hormone receptors that are activated by
endogenous lipid metabolites. Previous studies have demonstrated that PPAR-a activation stimulates keratinocyte
differentiation in vitro and in vivo, is anti-inﬂammatory, and improves barrier homeostasis. Recent studies have
shown that PPAR-b/d activation induces keratinocyte differentiation in vitro. This study demonstrated that topical
treatment of mice with a selective PPAR-b/d agonist (GW501516) in vivo had pro-differentiating effects, was anti-
inﬂammatory, improved barrier homeostasis, and stimulated differentiation in a disease model of epidermal
hyperproliferation. In contrast to PPAR-a activation, PPAR-b/d in vivo did not display anti-proliferative or pro-
apoptotic effects. The pro-differentiating effects persisted in mice lacking PPAR-a, but were decreased in mice
deﬁcient in retinoid X receptor-a, the major heterodimerization partner of PPAR. Furthermore, in vitro PPAR-b/d
activation, aside from stimulating differentiation-related genes, additionally induced adipose differentiation-related
protein (ADRP) and fasting induced adipose factor (FIAF) mRNA in cultures keratinocytes, which was paralleled by
increased oil red O staining indicative of lipid accumulation, the bulk of which were triglycerides (TG). Comparison
of differentially expressed genes between PPAR-b/d and PPAR-a activation revealed distinct proﬁles. Together,
these studies indicate that PPAR-b/d activation stimulates keratinocyte differentiation, is anti-inﬂammatory,
improves barrier homeostasis, and stimulates TG accumulation in keratinocytes.
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The peroxisome proliferator-activated receptors (PPAR)
belong to a subset of the nuclear hormone receptor (NHR)
superfamily (Class II receptors), which heterodimerize with
the retinoid X receptor (RXR) (Mangelsdorf et al, 1995;
Kersten et al, 2000; Chawla et al, 2001) Several members of
this subset of NHR have been shown to modulate
cutaneous homeostasis. For example, thyroid receptor
(TR), retinoid acid receptor (RAR), and vitamin D receptor
(VDR) are well-known regulators of epidermal growth and
differentiation (Pillai et al, 1991; Blumenberg et al, 1992;
Torma et al, 1993; Fisher et al, 1996), and activators of the
latter two receptors are currently employed to treat a variety
of skin diseases (Fritsch et al, 1992; Kragballe et al, 1992;
Orfanos et al, 1997; Saurat et al, 1999). Further support for
the importance of class II NHR in cutaneous homeostasis
derives from a mouse model with spatially and temporally
controlled deficiency of RXR-a, the major heterodimeriza-
tion partner for class II NHR. These mice display abnormal
skin development, epidermal hyperplasia, cutaneous in-
flammation, and alopecia (Li et al, 2000, 2001). Therefore,
substantial evidence supports the importance of class II
NHR as critical regulators of cutaneous homeostasis.
A number of NHR were first described before their
ligands had been identified, which coined the term ‘‘orphan’’
receptors. After ligand identification, it became clear that
many ligands of class II ‘‘orphan’’ NHR are lipid metabolites
and therefore they are ‘‘liposensors’’. Medium- to long-
chain fatty acids, eicosanoids, and isoprenoids derived
from cholesterol synthesis, such as farnesol, are activators
of the PPAR (Schoonjans et al, 1996; Forman et al, 1997;
Hanley et al, 2000). Previous studies have demonstrated
that the epidermis is an active site of cholesterol and fatty
acid synthesis (Feingold, 1991; Hurt et al, 1995), raising the
possibility that endogenous lipids produced in keratinocytes
might activate PPAR and thereby regulate gene expression.
In support of this hypothesis, results from our laboratory
Abbreviations: ADRP, adipose differentiation-related protein; CE,
cornified envelope; FIAF, fasting induced adipose factor; HPTLC,
high-performance thin layer chromatography; IL, interleukin; LPS,
lipopolysaccharide; NHR, nuclear hormone receptor; PCNA, anti-
proliferating cell nuclear antigen; PPAR, peroxisome proliferator-
activated receptor; RXR, retinoid X receptor; TEWL, transepidermal
water loss; TG, triglycerides; TPA, 12-O-tetradecanoylphorbol-13-
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have demonstrated that activation of PPAR-a by fatty acids,
isoprenoids, and drugs accelerates fetal skin development,
induces differentiation in keratinocytes, inhibits inflamma-
tion, and improves permeability barrier function (Hanley
et al, 2000; Komuves et al, 2000a, b). Importantly, these
effects did not occur in PPAR-a/ mice (Hanley et al,
2000), and fetal skin development was delayed in PPAR-a/
mice (Schmuth et al, 2002), demonstrating that these
effects are receptor mediated.
PPAR-b/d is expressed ubiquitously (Braissant et al,
1996, 1998). A drug that activates PPAR-b/d (GW501516)
has recently been shown to markedly increase serum HDL
levels whereas lowering serum triglyceride (TG) levels in
obese rhesus monkeys (Oliver et al, 2001). The increase in
serum HDL is thought to be due to the increased expression
of ABCA1, a transporter that is key in the efflux of
cholesterol out of cells to circulating HDL (Oliver et al,
2001). Furthermore, some but not all studies have
suggested a role for PPAR-b/d in regulating the differentia-
tion of adipocytes (Bastie et al, 2000; Barak et al, 2002), and
PPAR-b/d is a potent inhibitor of ligand-induced transcrip-
tional activity of PPAR-a (Barak et al, 2002). Pro-differentiat-
ing effects have been reported recently in cultured human
keratinocytes treated with PPAR-b/d agonists, such as
tetradecylthioacetic acid and L165041 (Westergaard et al,
2001). Additionally, over-expression of PPAR-b/d also
induced differentiation in cultured keratinocytes (Tan et al,
2001) and protected against cell death in vitro (Tan et al,
2001; Di-Poi et al, 2002). But little is known about the role of
PPAR-b/d in cutaneous homeostasis, and the effects of
PPAR-b/d activators on the epidermis in vivo. PPAR-b/d/
mice are difficult to obtain due to gestational lethality
(Peters et al, 2000; Michalik et al, 2001; Barak et al, 2002),
and surviving animals have residual PPAR-b/d RNA tran-
scripts (Peters et al, 2000). Nevertheless, despite partial
expression, these animals display an increased succept-
ibility to phorbol ester induced epidermal hyperplasia
(Peters et al, 2000), and a delayed wound healing response,
whereas epidermal differentiation and hair cycling are
normal (Michalik et al, 2001).
The purpose of this study was to evaluate the role of
exogenous PPAR-b/d activation on cutaneous homeostasis
and to delineate, if present, differences to PPAR-a activa-
tion. First, we determined the effects of topical PPAR-b/d
activation on proliferation, differentiation, epidermal cell
death, and permeability barrier function in normal skin.
Second, we tested the effects of PPAR-b/d activation in
disease models of cutaneous hyperproliferation and inflam-
mation. Third, we identified other genes and functions that
are regulated by PPAR-b/d activation in cultured keratino-
cytes. The results indicated both similarities and differences
in the effects of PPAR-b/d activation to those exerted by
PPAR-a activation on the epidermis.
Results
Effects of topical PPAR-b/d activators on normal murine
epidermis Previous studies by our laboratory demon-
strated that topical PPAR-a activators inhibit keratinocyte
proliferation and stimulate epidermal cell death and
keratinocyte differentiation in murine epidermis (Hanley
et al, 2000; Komuves et al, 2000). We therefore first assessed
the effects of PPAR-b/d activators on normal mouse skin
in vivo. After 6 d of topical application of GW501516,
epidermal thickness appeared slightly increased on light
microscopy of hematoxylin and eosin stained paraffin
sections (Fig 1a) but no significant increase in epidermal
thickness was detectable when the distance between the
basement lamina and the lower stratum corneum (SC) was
quantitated (Fig 1b). While the pool of proliferating cells
transiently increased after 3 d of treatment, it was un-
changed after 6 d (Fig 1c), whereas epidermal cell death
detected by TUNEL staining was unchanged (Fig 1h). These
results contrast with the known anti-proliferative and pro-
apoptotic effects of topical PPAR-a (Komuves et al, 2000).
Next, we examined the effects of GW1514 on epidermal
differentiation. Increased expression of filaggrin and loricrin
protein was detected by immunohistochemistry in mouse
skin topically treated with GW1514 for 6 d (Fig 1d).
Treatment with GW1514 for shorter periods of time also
increased mRNA levels of filaggrin, a keratinocyte differ-
entiation marker, with increases observed after 3 d of
treatment (Fig 1e). Thus, similar to PPAR-a activators,
PPAR-b/d activators stimulate keratinocyte differentiation.
Because many putative PPAR-specific activators pro-
miscuously activate other PPAR, we next assessed whether
the effects of topical GW1514 on differentiation were due to
activation of PPAR-a. Similar to wild-type animals, the
PPAR-b/d activator, GW1514, increased expression of
loricrin and filaggrin in the epidermis of PPAR-a/ animals
(Fig 1f). This observation demonstrates that GW1514-
induced stimulation of keratinocyte differentiation in vivo is
not mediated by activation of PPAR-a.
Since PPAR-b/d null mice were not available for study,
we next assessed the effects of PPAR-b/d activation in mice
with a keratinocyte-targeted disruption of RXR-a, the
common heterodimerization partner of all PPAR, including
PPAR-b/d. In comparison to wild-type and PPAR-a/
mice, the GW1514-mediated increase in filaggrin and
loricrin expression was blunted in RXR-a deficient mice
(Fig 1g). Additionally, the increase in differentiation markers
induced by PPAR-a activators also declined in RXR-a
deficient mice in comparison to control mice (not shown).
Together, these results indicate that both PPAR-a and
PPAR-b/d activators utilize RXR-a to stimulate keratinocyte
differentiation. Moreover, the ability of PPAR-b/d activators
to stimulate differentiation in PPAR-a deficient mice, but not
in RXR-a deficient mice suggests that the stimulation of
differentiation induced by GW1514 is mediated by PPAR-b/
d, and not by activation of PPAR-a.
PPAR-b/d activation accelerates epidermal permeability
barrier repair The SC, as the outermost layer of the
epidermis, is the end product of keratinocyte differentiation
and mediates epidermal permeability barrier function
(Jackson et al, 1993). To test the potential functional
relevance of the effects of GW1514 on epidermal differ-
entiation we next determined the effect of topical treatment
with PPAR-b/d activators on the ability to restore barrier
homeostasis after barrier perturbation. After 3 d of topical
application of GW1514, we experimentally disrupted
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permeability barrier function either mechanically (tape
stripping), by solvent extraction (repeated topical acetone),
or by detergent treatment (repeated topical SDS), and
measured the recovery of TEWL over time. Regardless
of the method of barrier perturbation, barrier recovery
was accelerated (Fig 2), indicating a beneficial effect on
permeability barrier homeostasis.
PPAR-b/d activation stimulates differentiation in a model
of epidermal hyperproliferation In view of the beneficial
effect of GW1514 on barrier repair, we next asked whether
the cutaneous effects of GW1514 would translate into a
potential therapeutic benefit using an animal model of skin
disease. As seen in previous studies (Denda et al, 1996),
repeated disruption of the permeability barrier of hairless
mice by twice-daily topical acetone applications over 3 d
induced epidermal hyperplasia and impaired differentiation.
Topical treatment with GW1514 also stimulated an increase
in the expression of the differentiation markers, loricrin and
filaggrin (Fig 1a) in the hyperproliferative epidermis of those
mice. But again and in contrast to PPAR-a activators, the
PPAR-b/d activator did not alter epidermal proliferation or
epidermal thickness (Fig 3a–c). Thus, as in normal mouse
skin, activation of PPAR-b/d stimulates differentiation with-
out affecting proliferation in this model.
Increased PPAR-b/d expression in keratinocytes treated
with cytokines and UV-B irradiation Previous studies
reported decreased PPAR-a expression in UV-exposed
epidermis and in skin from patients with psoriasis (Rivier
Figure 1
Effects of a peroxisome proliferator-activated receptor (PPAR)-b/d agonist on epidermal morphology and differentiation. Skin of mice was
topically treated twice daily for 1–6 d with vehicle (acetone) or with GW1514. (a) Hairless mouse skin (wild-type), hematoxylin and eosin staining
(upper row) and anti-proliferating cell nuclear antigen (PCNA) staining (second row) at day 6. (b) Measurements of epidermal thickness. (c)
Quantification of PCNA positive nuclei data are presented as mean  SEM (n¼34), po0.05. (d) Filaggrin and loricrin protein expression
assessed by immunohistochemistry after topical application of GW1514 at day 6. (e) Filaggrin expression assessed by in situ hybridization after
topical application of GW1514 at day 3. (f) PPAR-a/mice and wild-type, filaggrin and loricrin expression was assessed by immunohistochemistry
at day 3. (g) Retinoid X receptor (RXR)-a/ mice and wild-type mice, loricrin expression was assessed by immunohistochemistry at day 3. (h) Hair-
less mouse skin (wild-type) at day 3 of topical treatment, TUNEL staining, scale bar 1cm¼50mm  20, upper row; 1 cm¼ 25mm  40, lower row.
PPAR-b/d ACTIVATION IN KERATINOCYTES 973122 : 4 APRIL 2004
et al, 1998; Kippenberger et al, 2001). We therefore
determined whether PPAR-b/d expression changes after
keratinocytes are exposed to LPS cytokines or UV-B
irradiation. Northern analysis revealed an increase in
PPAR-b/d mRNA levels under all of these pro-inflammatory
conditions (Fig 4a), whereas the expression of PPAR-a and
g was reduced (not shown). These observations suggest
that PPAR-b/d may be selectively altered during keratino-
cyte inflammation.
PPAR-b/d activation exerts cutaneous anti-inﬂammatory
activity Since prior studies demonstrated that PPAR-a
activators are anti-inflammatory in an animal model of
irritant contact dermatitis (Sheu et al, 2002), and PPAR-b/d
Figure 2
Effect of topical peroxisome proliferator-activated receptor-b/d activation on permeability barrier repair. Hairless mice were treated with
vehicle or GW1514 twice daily for 3 d. Subsequently, the animals were treated by either repeated application of cellophane tape stripping, repeated
acetone application, or by repeated sodium dodecyl sulfate (SDS) treatment until the transepidermal water loss (TEWL) reached 6–8 mg per cm2 per
h. TEWL was measured at 3 and 6 h after barrier disruption. Recovery of barrier function is expressed as a percentage of time zero and data are
presented as mean  SEM; (n¼ 12), po0.05, po0.01.
Figure 3
Effects of a peroxisome proliferator-activated receptor-
b/d activation in mouse model of epidermal hyperplasia
and impaired differentiation. Hairless mice underwent
repeated barrier disruption by topical acetone treatment for
3 d. Subsequent GW1514 was applied topically twice daily
for 3 d. (a) Epidermal morphology including hematoxylin
and eosin staining, proliferating cell nuclear antigen (PCNA)
staining and immunohistochemistry for filaggrin and
loricrin. (b) Quantification of PCNA positive nuclei. (c)
Measurements of epidermal thickness. Data are presented
as mean  SEM (n¼3).
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is increased after cytokine treatment, after UV-B exposure
and in psoriasis (Rivier et al, 1998), we next assessed the
potential anti-inflammatory effects of GW1514 in a model of
inflammatory skin disease. We experimentally induced
irritant contact dermatitis by topical applications of the
phorbol ester, TPA, to the ears of CD1-mice. Both ear
thickness (Fig 4b, c) and ear weight (not shown) markedly
increased after a single TPA application (approximately
2-fold) accompanied by a mixed cellular infiltrate containing
neutrophils on light microscopy (Fig 6c). Treatment with
GW1514 significantly reduced the magnitude of these TPA-
induced changes, indicating an anti-inflammatory effect of
GW1514 (Fig 4b, c). Moreover, the extent of the reduction
in inflammation produced by the PPAR-b/d agonists
approached the anti-inflammatory effects of the topical
glucocorticoid, clobetasol, in this model (Fig 4c). Together,
these results demonstrate that topical PPAR-b/d activation
exerts anti-inflammatory effects in a model of irritant
contact dermatitis, comparable to those of a potent topical
glucocorticoid.
Effects of PPAR-b/d activation on keratinocytes in
vitro The above in vivo studies in mice demonstrate
important PPAR-b/d effects on cutaneous homeostasis. To
further explore which genes may be regulated in keratino-
cytes by PPAR-b/d, we used spotted cDNA microarrays to
assess the effects of PPAR-b/d activation on keratinocyte
gene expression in a comprehensive fashion. When primary
cultured keratinocytes were treated with a PPAR-b/d
agonist, using arrays comprising a total of 42,432 cDNA
sequences, representing 29,778 independent genes based
on Unigene Build 155, we observed a 4-fold change (either
up or downregulation) in the expression of 258 cDNAs at 6 h
and a 4-fold change in the expression of 120 cDNAs at 48 h.
These results indicate that PPAR-b/d activation has highly
selective effects on keratinocyte gene expression.
Using hierarchical cluster analysis (average linkage
metric) (Eisen et al, 1998), we identified a number of
keratinocyte differentiation-related genes, including involu-
crin, small proline-rich region protein (SPRR) 1B, SPRR 2C,
SPRR 3, desmoplakin, envoplakin, cystatin A, and annexin
A1, which increased with PPAR-b/d activation (Table Ia).
These genes have in common that they encode for proteins
that are cross-linked into the cornified envelope (CE) as
keratinocytes transform into anucleate corneocytes during
differentiation. Many of these genes also map to the same
chromosomal region, the epidermal differentiation complex
(EDC) on chromosome 1q21 (Volz et al, 1993). A represen-
tative cluster from these experiments, demonstrating
changes in several differentiation-related genes is shown
in Fig 5a. Notably, the changes in differentiation-related
genes occur at later time points; i.e., 24–48 h (Fig 5a).
We used independent assays to confirm the results
obtained on microarray hybridization. By both northern and
western analyses, GW1514 treatment similarly increased
mRNA and protein levels of involucrin, a marker of
keratinocyte differentiation (Fig 5c,d), confirming previous
results (Westergaard et al, 2001). Strikingly, the increase in
involucrin by GW1514 was more effective than the effects of
switching from low (0.03 mM) to high (1.2 mM) calcium
concentrations in the medium (Fig 5c), a standard method
to induce keratinocyte differentiation (44). Finally, GW1514
treatment resulted in an increase of PPAR-b/d mRNA,
indicating a positive feedback loop (not shown). These
results indicate that activation of PPAR-b/d increases
a number of differentiation-related genes in cultured
keratinocytes.
Effects of PPAR activation on keratinocyte lipid meta-
bolism Whereas the microarray experiments demon-
strated that PPAR-b/d regulates a number of keratinocyte
differentiation-related genes, in many instances the genes
Figure 4
Peroxisome proliferator-activated receptor (PPAR)-b/d expression
and cutaneous inflammation. (a) Human keratinocytes were incu-
bated with lipopolysaccharide (LPS), interleukin (IL)1-b, tumor necrosis
factor (TNF)-a or exposed to UV-B irradiation and poly-A RNA was
isolated for northern blot analysis. Data are presented as mean  SEM
(n¼ 3–4), po0.05, po0.01. (b) Hematoxylin and eosin-stained
sections of normal mouse ear, 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced irritant dermatitis, clobetasol treated and GW1514
treated. TPA treatment results in a marked increase in ear thickness
and a prominent mononuclear cell infiltrate in the dermis. GW1514
treatment reduces ear thickness and the number of inflammatory cells.
(c) Quantification of ear thickness measurements. Data are presented
as mean  SEM; n¼ 4; po0.001.
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effected were EST with unknown functions. Yet, another
category of genes, which we noted to consistently increase
with PPAR-b/d treatment, included adipose differentiation-
related protein (ADRP) and fasting induced adipose factor
(FIAF) mRNA, which were consistently increased at both
early and late time points (6–48 h) after PPAR-b/d activation
(Table 1b, Fig 5b). The apparent stimulation of ADRP and
FIAF again was confirmed by northern blotting (Fig 5e). A
similar increase in ADRP and FIAF occurred when kerati-
nocytes were treated with a PPAR-a activator (not shown).
ADRP is associated with intracellular lipid droplets
(Brasaemle et al, 1997; Frolov et al, 2000; Corsini et al,
2003; Schmuth, 2003) and reportedly facilitates fatty acid
binding and uptake in COS-7 cells (Gao et al, 2000), as well
as the transfer of triacylglycerol from lipofibroblasts to
surfactant producing epithelial cells in the lung (Schultz
et al, 2002). FIAF was previously reported to be increased in
liver and white adipose tissue during fasting but the function
of this protein is unknown. FIAF levels decreased in the
plasma with high fat feeding, an effect directly opposite that
observed with leptin (Kersten et al, 2000). Because of the
potential role of ADRP and FIAF in lipid metabolism, we next
assessed lipid storage in PPAR-b/d-activated keratinocytes,
and compared these effects with PPAR-a activation. Lipids
did not accumulate during the first 48 h of treatment with
either PPAR-b/d or PPAR-a agonist as indicated by oil red O
staining (not shown). Keratinocytes treated for more
prolonged periods (6 d) in the presence of either GW1514
or WY-14,643, however, showed increased oil red O staining
in comparison to vehicle-treated controls grown in the
presence of either palmitic acid or fetal calf serum (Fig 6a).
HPTLC of keratinocytes treated for 6 d with GW1514 or Wy-
14,643 showed an increase in TG (Fig 6b) without changes
in other lipid species such as fatty acids, phospholipids or
ceramides (not shown). Finally, to determine whether lipid
accumulation also occurs in the epidermis in vivo, we
treated hairless mice topically with either PPAR-a or PPAR-
b/d activators. Nile red staining of frozen skin sections from
these animals revealed increased lipid staining in PPAR-
b/d and PPAR-a activator-treated animals versus vehicle-
treated controls (Fig 6c). These results indicate increased
lipid accumulation in keratinocytes exposed to either PPAR-
a or PPAR-b/d activators.
These results prompted us to ask whether keratinocytes
acquire an adipocyte phenotype when exposed to PPAR
activators. Classical markers of adipocyte differentiation
such as aP2, adipsin, PPAR-g, resistin, and leptin, however,
were not found to be present on either microarray or
northern blot analysis in keratinocytes treated with either
PPAR-a or PPAR-b/d activators (not shown). Yet, the
epidermal cell that is most efficient in lipid storage is the
sebocyte. Therefore, we next asked whether the increased
accumulation of TG and the increased expression of ADRP
and FIAF indicate differentiation of cultured keratinocyte
towards a sebocyte lineage (Elias et al, 1987; Ferraris et al,
1997; Merrill et al, 2001) under the influence of PPAR
activation. Searching our microarray database for markers
of sebocyte differentiation (Zouboulis et al, 1999), we found
keratin 7, keratin 19, and epithelial membrane antigen (EMA)
to be essentially unchanged in our experimental system
(Table Ic), which in the case of keratin 7 was additionally
confirmed on northern blot analysis (not shown). Thus, the
increased storage of TG and the expression of ADRP and
FIAF do not indicate transdifferentiation of keratinocytes
into either sebocytes or adipocytes.
Table I. PPAR-b/d activation modulates differentiation-related
genes in primary cultured keratinocytes
Description
GeneBank
accession no.
PPAR-b/d
(fold change)
(a) Markers of keratinocyte differentiation
Annexin A1 H63077 2.6
Cystatin A W72207 2.7
Desmoplakin H90899 2.1
Envoplakin AA029418 2.0
Involucrin AI417983 2.8
Keratin 1 AA706022 0.8
Keratin 10 AA42454 1.4
Periplakin AI682360 0.6
SPRR 1B AA447835 8.0
SPRR 2C AA399647 6.7
SPRR 3 AI278521 2.2
Transglutaminase-1 AI652954 1.3
(b) Adipocyte genes
ADRP AA700054 68
FIAF W30988 12.2
(c) Markers of sebocyte differentiation
Keratin 7 AA489869 1.2
Keratin 19 AA464250 1.4
EMA AA975768 1.1
Total RNA from keratinocytes was hybridized to a set of 42.432 human
cDNAs in a microarray format. Log transformed and normalized ratios
between the combined signals from GW1514 and vehicle-treated cells
after 48 h of culture are shown. PPAR, peroxisome proliferator-activated
receptor; ADRP, adipose differentiation-related protein; FIAF, fasting
induced adipose factor; EMA, epithelial membrane antigen; ApoE,
apoprotein E; SPRR, small proline-rich protein.
Figure 5
In vitro effects of peroxisome proliferator-activated receptor (PPAR)-b/d activation on keratinocyte gene expression. (a) Cluster containing
differentiation-related genes. (b) Cluster containing adipose differentiation-related genes. Total RNA was reverse transcribed, fluorescent labeled
and hybridized to a set of human cDNAs in a microarray format. Color-coded expression table of the genes selected by cluster analysis from various
time points (representative of duplicate arrays) after PPAR-b/d activation, visualized by TreeView (Eisen et al, 1998). Abscissa, time points; ordinate,
genes. Increase, red; decrease, green. (c, d) Total cellular RNA or protein were isolated from cultured keratinocytes after treatment with GW1514 and
involucrin levels were measured by (c) northern and (d) western blot analysis. Northern data are presented as ratio to GAPDH levels. Ca2þ , high
calcium medium (1.2 mM). Data are presented as mean  SEM (n¼3), po0.05, po0.005. (e) Total RNA was isolated from cultured
keratinocytes 24 h after treatment with GW1514 and adipose differentiation-related protein (ADRP) or fasting induced adipose factor (FIAF) mRNA
levels were measured by northern blot analysis and compared to GAPDH levels.
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Comparison of PPAR-a versus PPAR-b/d activators in
keratinocytes Finally, in view of the overlapping effects of
PPAR-a and PPAR-b/d activators on the epidermis, we
asked which genes respond similarly or differently to PPAR-
a or PPAR-b/d activators. To this end, using hierarchical
cluster analysis (average linkage metric) (Eisen et al, 1998),
comparing the 6 and 48 h time points, we observed
34 cDNAs selectively being decreased by PPAR-a (50%
decrease) and two cDNAs by PPAR-b activation (50%
decrease). In contrast, only five cDNAs were selectively
increased by PPAR-a (2-fold increase) and two cDNAs
by PPAR-b/d activation (2-fold increase) (Table II). Thus,
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whereas the patterns of genes induced and repressed by
PPAR-a and PPAR-b/d activation are largely overlapping,
both PPAR-a and PPAR-b/d also have selective effects on
certain subsets of genes and these differential effects more
commonly involve repression of gene expression. Together,
these results indicate that there are distinct patterns of
genes that are repressed or induced by PPAR-a and PPAR-
b/d activation in keratinocytes.
Discussion
Previous studies by other investigators have shown that
activation of PPAR-b/d stimulates the differentiation of
keratinocytes in culture (Westergaard et al, 2001). In this
study, we extend these observations and demonstrate that
the topical treatment of mice with a PPAR-b/d activator
stimulates epidermal differentiation in vivo. The expression
of loricrin and filaggrin, two well-recognized markers of
keratinocyte differentiation, were increased by the topical
application of GW1514, a selective PPAR-b/d activator (Fig
1d–f). Moreover, we demonstrate that this increase in
loricrin and filaggrin expression is receptor mediated. In
RXR-a deficient mice the stimulation of differentiation
induced by GW1514 treatment was blunted (Fig 1f). RXR-
a is the most abundant isoform of RXR in the epidermis and
RXR is an obligate partner required for the regulation of
gene expression by PPAR. Hence, the decrease in the
ability of GW1514 to induce differentiation in RXR-a
deficient mice indicates that the effects of GW1514 are
receptor mediated. Previous studies by our laboratory have
shown that clofibrate and other PPAR-a activators stimulate
epidermal differentiation in wild-type but not in PPAR-a
deficient mice. In this study, we demonstrate that GW1514
stimulates differentiation in PPAR-a deficient mice indi-
cating that the effect of GW1514 on differentiation is
not mediated by PPAR-a. Thus, these experiments taken
together strongly suggest that the stimulation of epidermal
differentiation by GW1514 is mediated by PPAR-b/d.
Determining the effect of GW1514 in PPAR-b/d deficient
mice would be the ideal experiment to definitively prove
that the effect of GW1514 is mediated by PPAR-b/d, but
unfortunately such animals are not available for study
(homozygote PPAR-b/d knockout mice have a high mortality
rate and therefore animals with a localized deficiency of
PPAR-b/d need to be created).
The formation of a competent permeability barrier, which
resides in the extracellular compartment of the SC, is the
end product of keratinocyte differentiation (Eisinger et al,
1993; Jackson et al, 1993). Pre-treatment with GW1514
accelerated the restoration of permeability barrier function
following barrier disruption by tape stripping, solvent
treatment or detergent treatment (Fig 2). This improvement
in permeability barrier homeostasis confirms the biological
importance of the pro-differentiating effects of PPAR-b/d
activation. Additionally, GW1514 induced differentiation in
an animal model of epidermal hyperplasia and abnormal
differentiation (Fig 3). This ability of GW1514 to stimulate
differentiation in abnormal epidermis suggests that PPAR-b/
d agonists may be useful in the treatment of a variety of skin
disorders characterized by disturbed differentiation.
In addition to stimulating epidermal differentiation, this
study also demonstrates that PPAR-b/d activation is anti-
inflammatory. In a mouse model of irritant contact dermatitis
(TPA-induced inflammation of ears), treatment with GW1514
markedly decreased inflammation (Fig 4c,d). In line with
these results, Peters et al (2000) have previously reported
that PPAR-b/d deficient mice fed with the NSAID sulindac
have an increased inflammatory response to phorbol ester
(TPA) treatment when compared to wild-type mice, which
suggests that PPAR-b/d plays a key role in downregulating
inflammation. Together, these results suggest that PPAR-b/d
activators may be useful therapeutic agents to reduce
inflammation in the skin and perhaps in other tissues.
Pertinently, whereas agents that induce inflammation,
such as cytokines and UV light, reduce the expression of
PPAR-a and PPAR-g in cultured human keratinocytes, the
expression of PPAR-b/d is increased (Fig 4a) (Tan et al,
2001). Moreover, in psoriatic skin, the expression of PPAR-
b/d is increased whereas the expression of PPAR-a
Figure 6
Effects of peroxisome proliferator-activated receptor activation on epidermal lipids. (a) Cultured, 40%–60% confluent keratinocyte were
treated with 8 mM GW1514 or 20 mM Wy-14,643 for 6 d. Cells were fixed using 3.7% paraformaldehyde and incubated with oil red O (Sigma, 0.5 g in
100 mL isopropanol stock solution diluted 6 : 4 with water) for 1 h. (b) High-performance thin layer chromatography was used for the analysis of lipid
extracts from cultured cells. One hundred micromolar palmitic acid (upper graph); 10% fetal calf serum (FCS) (lower graph). (c) For in vivo
assessment, Nile red was applied to 5 mm frozen sections of skin that had been topically treated twice daily with 4 mM GW1514 for 3 d. Sections
were examined using a fluorescence microscope equipped for epifluorescence.
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and PPAR-g is decreased (Rivier et al, 1998). The increased
expression of PPAR-b/d during cutaneous inflamma-
tion makes it an attractive therapeutic target for the
treatment of diseases that are characterized by cutaneous
inflammation.
To gain further insights into the effect of PPAR-b/d
activation on keratinocytes we carried out microarray
experiments. As expected, we found that the expression
of genes that are well known to increase during keratinocyte
differentiation, were increased by treatment with GW1514.
Specifically, we found that involucrin, SPRR 1B, SPRR 2C,
SPRR 3, annexin A1, cystatin A, desmoplakin, and
envoplakin were increased by PPAR-b/d activation (Table
Ia). It should be noted that the increase in the expression of
these differentiation-related proteins was a late effect (48 h)
of PPAR-b/d activation (Fig 5a). This suggests that the
increased expression of these proteins is not a direct effect
of PPAR-b/d on the promoter of these genes, but rather was
due to PPAR-b/d activation stimulating other transcription
factors. In our studies of PPAR-a activators, we observed
that the increase in the expression of keratinocyte differ-
entiation markers induced by PPAR-a activation also was a
late effect (not shown). Furthermore, the PPAR-a induced
increase in the expression of involucrin required an intact
AP-1 response element in the involucrin promoter (2011 to
–2017) suggesting that the effect of PPAR-a was not a direct
effect, but rather was mediated by a secondary increase in
AP-1 activity (Hanley et al, 2000).
To our surprise the expression of two genes that are well
known to be expressed in adipocytes, FIAF and ADRP, were
markedly increased in keratinocytes treated with GW1514
(Table Ib; Fig 5b, e). FIAF is expressed in adipocytes and its
expression is increased during adipocyte differentiation,
during fasting, and in mouse models of obesity and
diabetes (Kersten et al, 2000). The biological function of
FIAF is unknown but it is presumed to play a role in lipid
metabolism. ADRP is a membrane-associated fatty acid
binding protein that facilitates the transport of long chain
fatty acids (Frolov et al, 2000; Gao et al, 2000). Its
expression is induced during adipocyte differentiation but
it is also expressed in other tissues that are involved in TG
and fatty acid metabolism (Yuspa et al, 1988; Brasaemle
et al, 1997). Cells that either store or transport lipid express
ADRP and it has been proposed that ADRP associates with
lipid vacuoles (Yuspa et al, 1988; Brasaemle et al, 1997).
Recent studies have suggested that ADRP plays an
important role in the up take of surfactant lipids by alveolar
type II epithelial cells (Schultz et al, 2002). Studies have
shown that there are NHR response elements in the
promoter of ADRP and that PPAR activation directly
stimulates ADRP expression (Eisinger et al, 1993). That
ADRP is a direct downstream target of PPAR-b/d is very
compatible with the early increase in ADRP expression that
we see with GW1514 treatment (Fig 5b).
Because of the link between the expression of FIAF,
ADRP, and lipids we examined the effect of PPAR-b/d
activation on lipid accumulation. In both cultured human
keratinocytes and mouse epidermis we found that treat-
ment with GW1514 resulted in the increased accumulation
of lipids that were predominantly TG (Fig 6) similar to
previous results from macrophages (Vosper et al, 2001) and
Table II. Differential gene regulation PPAR-a versus PPAR-b
Description
GeneBank
accession no.
(a) Selectively decreased by PPAR-a
3-a-hydroxysteroid dehydrogenase AA916325
FXYD domain containing ion transport regulator 3 AA126115
EST W68630
EST R51067
EST AA757672
Ephrin-A1 AA857015
EST T56713
EST N21217
EST AA598615
EST AA479954
ATP synthase, Hþ transporting, vacuolar R73402
Chromosome 20 open reading frame 155 N29545
Non-metastatic cells 5 AA453579
ATP synthase, Hþ transporting, mitochondrial AA431433
Ribosomal protein S19 H41165
EST H97921
EST AA157112
EST AA487934
EST AA399166
EST H58959
EST AA399372
ATPase, Naþ /Kþ transporting AA598814
EST H04815
EST AA011400
EST AA418593
cDNA DKFZp434P0235 AA169444
Hypothetical protein LOC55565 AA446446
EST AA872402
HBV associated factor AA447671
Janus kinase 1 AA284634
Selenoprotein W, 1 AA283629
EST N91527
EST AI053614
EST AA983191
(b) Selectively decreased by PPAR-b
Topoisomerase (DNA) II a 170 kDa AA504348
EST AA172076
(c) Selectively increased by PPAR-a
EST N48689
EST H38977
EST AA406059
EST AA172076
EST N32071
(d) Selectively Increased by PPAR-b
SPRR 1B AA447835
EST W68630
EST, expressed sequence tags.
PPAR-b/d ACTIVATION IN KERATINOCYTES 979122 : 4 APRIL 2004
keratinocytes exposed to irritants (Corsini et al, 2003). Since
studies by other investigators have shown that activation of
PPAR-b/d stimulates adipocyte differentiation (Bastie et al,
2000), we assessed if treatment of keratinocytes with
PPAR-b/d activator was inducing an adipocyte phenotype
in keratinocytes. To this end, we determined if the
expression of other genes that are expressed in adipocytes
were increased in GW1514-treated keratinocytes. Adipsin,
resistin, leptin, and aP2, specific adipocyte markers, were
not expressed in either GW1514-treated or control kerati-
nocytes. Keratinocytes also have the potential to become
sebocytes, which store and secrete lipids. To determine if
PPAR-b/d activation was stimulating the conversion of
keratinocytes to sebocytes (Elias et al, 1987; Ferraris et al,
1997; Merrill et al, 2001), we determined if the expression of
sebocyte markers were increased in keratinocytes treated
with GW1514. Keratin 7, keratin 19, and EMA are sebocyte
markers and the expression of these genes were not
increased in keratinocytes by PPAR-b/d activator treatment
(Table Ic). Thus, PPAR-b/d activation stimulates lipid
accumulation in keratinocytes, but it is not clear at this
time why this occurs or its functional significance.
Previous studies by our laboratory have shown that
PPAR-a activators stimulate keratinocyte differentiation,
improve permeability barrier homeostasis, and are anti-
inflammatory (Hanley et al, 2000; Komuves et al, 2000a, b).
Moreover, in this study we observed that the PPAR-a acti-
vator, WY14,643, also stimulates the expression of ADRP
and FIAF (not shown) and the accumulation of lipids (Fig 6).
Additionally, as previously reported by others, PPAR-a
activation increases lipid metabolism in a skin equivalent
model (Rivier et al, 2000). But there are differences between
the effects of PPAR-a and PPAR-b/d activation. Although
PPAR-a activation inhibits epidermal proliferation, PPAR-b/d
activation does not affect in vivo proliferation. Accordingly,
when one examines the microarray data, although there are
many similarities in the pattern of genes induced and
repressed by PPAR-a and PPAR-b/d activation there are
also differences (Table II). Thus, although there will be a
great deal of overlap and redundancy in the actions of
PPAR-a and PPAR-b/d on the epidermis there will also be
differences.
In the epidermis, a multi-step process of keratinocyte
differentiation occurs that ultimately forms the outermost
layer of the skin, the SC, which consists of protein-enriched
corneocytes embedded in a continuous, lipid-enriched,
extracellular matrix (Jackson et al, 1993; Steinert, 2000).
Thus, the SC consists of corneocytes (the bricks) and
extracellular lipid membranes (the mortar) that serve as a
barrier between the organism and the environment and a
competent barrier is required for survival (Jackson et al,
1993). The lipid enriched extracellular lamellar membranes
are derived from the secretion of lamellar bodies from
stratum granulosum cells and provide the permeability
barrier to water transit. The corneocytes form a CE by the
enzyme transglutaminase extensively cross-linking loricrin,
involucrin, and other proteins to form a rigid structure that
provides strength and resistance to the SC. The protein
versus lipid arms of keratinocyte differentiation and SC
formation are traditionally viewed as concurrent, but
independent processes. But the ability of lipids, such as
long chain fatty acids, to activate PPAR-a and PPAR-b/d
and the recent data (including this paper) demonstrating
that these transcription factors can stimulate keratinocyte
proteins required for CE formation, suggest that there may
be cross-talk between the two arms of keratinocyte
differentiation (Hanley et al, 2000; Schmuth et al, 2002).
One can speculate that as lipid precursors accumulate in
stratum granulosum cells, these lipids or their metabolites
could activate NHR, which in turn stimulate other aspects of
keratinocyte differentiation, such as increasing the expres-
sion of the structural proteins required to form the CE. This
would allow for the coordinated formation of the SC.
In summary the results of this and previous studies demon-
strate that PPAR-a and PPAR-b/d activation stimulates
keratinocyte differentiation, improves permeability barrier
homeostasis, increases lipid accumulation in keratinocytes,
and is anti-inflammatory, whereas we also show differing
effects on other parameters such as epidermal proliferation
in vivo. It is likely that these profiles will be beneficial for the
treatment of a variety of cutaneous disorders and therefore
PPAR-a and/or PPAR-b/d activators may be useful ther-
apeutic agents for the treatment of skin diseases.
Materials and Methods
Cell culture Second-passage keratinocytes isolated from new-
born foreskins were cultured in serum-free keratinocyte growth
medium (Clonetics, San Diego, California). Cells were treated at
70%–100% confluency with either the PPAR-a activator Wy-
14,643 (20 mM, Sigma, St Louis, Massachussets), the PPAR-b/d
activator GW1514 (8 mM, GlaxoSmithKline, Triangle Park, North
Carolina), tumor necrosis factor (TNF)-a (100 ng per mL, R&D
Systems, Minneapolis, Minnesota), interleukin (IL)1-b (50 ng per
mL, R&D Systems), lipopolysaccharide (LPS, 100 mg per mL, Difco,
Detroit, Michigan) or exposed to UV-B irradiation (30 mJ per cm2,
FS-20/T12 tubes). Control keratinocytes were treated with vehicle
(0.05% ethanol) or sham irradiated.
Animal models Animals employed in these studies were 6–8-wk-
old male hairless mice (Simonsen Laboratories, Gilroy, California),
CD-1 mice (Charles River, Wilmington, Massachusetts), PPAR-a/
mice (Lee et al, 1995), and RXR-a/ mice (Li et al, 2000, 2001).
Age matched mice from the same genetic background were used
as controls. The animal procedures were approved by the local
Animal Studies Subcommittee and were performed in accordance
with their guidelines. For topical treatment GW1514 was dissolved
in an acetone or dimethyl sulfoxide (DMSO) vehicle at a
concentration of 4 mM and topically applied to the flank of mice
twice daily for 1–6 d. Barrier disruption was induced in hairless
mice by application of acetone or sodium dodecyl sulfate (SDS)-
soaked cotton balls until the transepidermal water loss (TEWL)
reached 6–8 mg per cm2 per h. Alternatively, the barrier was
disrupted by repeated tape stripping with cellophane tape. TEWL
recovery was determined at 3 and 6 h following disruption. Chronic
barrier disruption was induced in hairless mice by twice daily
application of acetone-soaked cotton balls until the TEWL reached
6–8 mg per cm2 per h for 3 consecutive days. Subsequently,
repeated acetone treatment was discontinued and the area was
treated with 4 mM GW1514 as above. Irritant contact dermatitis
was induced in CD1 mice by a single topical application of 10 mL of
0.03% (wt/vol in acetone) 12-O-tetradecanoylphorbol-13-acetate
(TPA) on the inner and outer surfaces of the left ears of male mice.
The right ears were treated with vehicle alone (acetone). GW1514
was dissolved in acetone at a concentration of 4 mM and topically
applied to both the left and right ears at 45 min and 4 h following
the inflammatory insult with TPA in one group of animals. In a
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separate set of animals acetone was applied to both left and right
ears as a vehicle control. A total of 20 ml of GW1514 or vehicle was
applied to each surface of each ear. At 18 h, when TPA-induced
inflammation is maximal, ear thickness was measured with a digital
caliper (Mitutoyo Corp., Tokyo, Japan), followed by 6 mm full skin
biopsies for weight determinations. Ear swelling, measured by
thickness and weight, was calculated according to the following
equation: Ear swelling (%)¼ 100(ab)/b; a¼ thickness or weight of
treated left ear; b¼ thickness or weight of control right ear. Mouse
skin sections (6 mm) were fixed in 4% formaldehyde and stained
either with hematoxylin and eosin or used for immunohistochem-
istry (see below). Photographs were taken with a Zeiss microscope
(Jena, Germany).
Northern blot analysis Poly-A RNA was purified using oligo(dT)
cellulose (Amersham–Pharmacia, Piscataway, New Jersey) and
hybridized with 32P-labeled cDNA probes as described previously
(Beigneux et al, 2000).
Microarray analysis Aliquots of 30 mg keratinocyte total RNA
were reverse transcribed in the presence of amino-allyl- dUTP and
coupled to fluorescent Cy-dyes (Amersham) as described pre-
viously (Hughes et al, 2001). We compared control RNA (vehicle-
treated keratinocytes) to RNA from cells treated for 3, 6, 16, 24,
and 48 h after addition of nuclear hormone receptor activators to
the medium. A set of 42,432 human cDNA clones comprising
29778 genes as well as expressed sequence tags (EST) from
Research Genetics (Huntsville, Alabama) were spotted onto
polylysine-coated glass slides by a costum made arrayer robot
kindly made available by Joe deRisi (University of California, San
Francisco). Hybridization in a buffer containing 3  SSC, 0.25%
SDS, 0.75 mg per mL polyadenylic acid, and 0.5 mg per mL Cot-1
DNA, was carried out in a sealed hybchamber (GeneMachines,
San Carlos, California) overnight at 63–651C. Fluorescence
intensity was detected using the GenePix 4000B Array Scanner
(Axon Instruments, Union City, California). Resulting data files were
evaluated by a series of quality-control criteria including replicate
cDNA spots on the same slide, technical replicates (same RNA
independently labeled and hybridized to different slides), and
exclusion of array images with obvious blemishes (control
procedures relating to the image itself). The results reported are
comprised from experiments involving primary cultured keratino-
cytes from multiple donors (biological replicates), samples, and
arrays. Computational analysis of the results was carried out as
desribed below (Data analysis).
In situ hybridization Digoxigenin-labeled RNA probes to detect
filaggrin mRNA were made from linearized cDNA sequences using
reagents supplied by Boehringer-Mannheim (Indianapolis, Indiana).
The sections were hybridized at 451C and binding of DIG-labeled
probes to the endogenous mRNA was detected by anti-DIG-
alkaline phosphatase (Boehringer-Mannheim), using 5-bromo-4-
chloro-3-indolyl phosphate/nitrotetrazolium blue substrate. Hybri-
dization with DIG-labeled sense control probes resulted in no
staining.
Immunohistochemistry Antibodies to filaggrin and loricrin were
purchased from BabCo (Richmond, California). For identification of
proliferating keratinocytes, paraffin sections were stained with a
biotinylated anti-proliferating cell nuclear antigen (PCNA) antibody
(CalTag Laboratories, Burlingame, California). TUNEL assay was
carried out using the in situ cell death detection kit from Roche
Molecular Biochemicals (Indianapolis, Indiana) using FITC-labeled
dUTP.
Western blot analysis Involucrin protein was detected by
incubation overnight at 41C with a monoclonal mouse anti-human
involucrin antibody (Sigma) as described previously (Hanley et al,
2000).
Lipid detection Nile red and frozen tissue embedding compound
(OCT) were from Miles Scientific Division (Naperville, Illinois). Nile
red was applied to 5 mm frozen sections, which were examined
using a Leitz fluorescence microscope equipped for epifluores-
cence (E. Leitz, Inc., Rockleigh, New Jersey). For visualization of
lipids in cultured keratinocytes, confluent keratinocytes were
cultured in the presence of 100 mM palmitic acid (in bovine serum
albumin 3 : 1) or in the presence of 10% fetal calf serum for 6 d and
then exposed to 8 mM GW1514 for 6 d. Subsequently, cells were
fixed using 3.7% paraformaldehyde and incubated with oil red O
(Sigma, 0.5 g in 100 mL isopropanol stock solution diluted 6 : 4 with
water) for 1 h. Alternatively, lipids were extracted from cultured
keratinocytes with the Bligh/Dyer method. They were spotted on
high-performance thin layer chromatography (HPTLC) Plates
(Merck, Gibbstown, NJ) along with known standards (Sigma
Chemical Co.) using a Linomat II Auto spotter (CAMAG Scientific
Inc., Wilmington, North Carolina). Neutral lipids (sterol ester,
triglyceride, free fatty acid, and free sterol) were sub-fractionated
in benzene : n-hexane (1 : 1, v/v) to 8 cm from the application site
followed by n-hexane : diethylether : acetic acid (70 : 30 : 1, v/v) to
5 cm from the application site. Ceramides and glucosylceramides
were sub-fractionated in chloroform : methanol : H2O (40 : 10 : 1,
v/v) to 2 cm from the application site, repeat to 5 cm, followed
by chloroform : methanol : acetic acid (47 : 2 : 0.5, v/v) to 8.5 cm,
and followed by n-hexane : diethylether : acetic acid (30 : 15 : 0.5, v/
v) to 8.5 cm. Phosphatidylcholine and sphingomyelin were sub-
fractionated in chloroform : methanol : 28% NH4OH (32 : 12 : 2.5, v/
v) to 8.5 cm from the application site. All separations were done in
a vertical developing chamber at room temperature. The plate was
then dipped in charring solution, charred, and quantitated with a
CAMAG Scanning Densitometer (CAMAG Scientific Inc.).
Data analysis For northern and western blot results statistical
significances were determined using the Student’s t test or the
Kruskal–Wallis test, as appropriate. For microarray experiments
background subtraction and computation of ratios was carried out
using GenePix 4.0 Software (Axon Instruments). Using NOMAD
(http://www.microarrays.org/software.html) and Cluster (Eisen
et al, 1998) the ratio of medians was normalized, and ratios
underwent a logarithm transformation for all the observed gene-
expression levels. Hierarchical clustering (average linkage metric)
was used to organize the data (Eisen et al, 1998).
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